Clinical trial • Phase III • Gastroenterology|Endocrinology
Clinical trial in Gastroenteropancreatic neuroendocrine tumor (well-differentiated, locally advanced or metastatic)
Phase III trial for Gastroenteropancreatic neuroendocrine tumor (well-differentiated, locally advanced or metastatic). 24 participants.
Overview
- Trial Therapeutic Area
- Gastroenterology|Endocrinology
- Trial Disease
- Gastroenteropancreatic neuroendocrine tumor (well-differentiated, locally advanced or metastatic)
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 16-05-2024
- First CTIS Authorization Date
- 28-05-2024
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 24
- Trial Duration For Participant
- 1013
Eligibility
Recruits 24 No vulnerable population selected (isVulnerablePopulationSelected=false).
- Vulnerable Population
- No vulnerable population selected (isVulnerablePopulationSelected=false)
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 33
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Netherlands
- Earliest CTIS Part Ii Submission Date
- 28-03-2024
- Latest Decision Or Authorization Date
- 28-05-2024
- Processing Time Days
- 61
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Internal medicine
- Principal Investigator Name
- Johannes Hofland
- Principal Investigator Email
- j.hofland@erasmusmc.nl
- Contact Person Name
- Johannes Hofland
- Contact Person Email
- j.hofland@erasmusmc.nl
Sponsor
Primary sponsor
- Full Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Nonalcoholic steatohepatitis (NASH) | Liver fibrosis
- Eloralintide for Hepatic impairment
- Vonafexor for Healthy volunteers|Renal impairment|Metabolic dysfunction-associated steatohepatitis (MASH)
- Bupropion hydrochloride; Naltrexone hydrochloride for Obesity|Weight regain after bariatric surgery
- ALGLUCOSIDASE ALFA for Pompe disease